Rare Biomarkers Specimen Collection and Stabilization

Rare Biomarkers Specimen Collection and Stabilization

Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach US$87.8 Billion by 2030

The global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$47.4 Billion in the year 2023, is expected to reach US$87.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$34.0 Billion by the end of the analysis period. Growth in the Circulating Tumor Cells (CTCs) segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.1 Billion While China is Forecast to Grow at 8.5% CAGR

The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$13.1 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Rare Biomarkers Specimen Collection and Stabilization: Advancing Precision in Biomedical Research

What Are Rare Biomarkers, and Why Is Specimen Collection and Stabilization Important?

Rare biomarkers are specific biological molecules found in limited concentrations in the body, often present in blood, urine, or tissue samples, that indicate a particular disease state, response to treatment, or genetic profile. These biomarkers are essential in the diagnosis, monitoring, and prognosis of various conditions, including cancer, genetic disorders, and neurodegenerative diseases. Detecting rare biomarkers can enable early disease detection, targeted therapies, and personalized medicine approaches. However, their low abundance makes them challenging to identify and measure, especially as they may degrade or change rapidly after specimen collection. Thus, proper specimen collection and stabilization are critical to preserving the integrity and reliability of these biomarkers for accurate analysis.

Effective collection and stabilization of rare biomarkers ensure that they remain unchanged from the moment they are sampled until they are analyzed. This process involves carefully selecting collection devices, using stabilizing agents, and following stringent protocols to prevent biomarker degradation. Improper handling can lead to inaccurate test results, misinterpretation of a disease state, or missed diagnosis, underscoring the importance of stability in precision medicine and research. The growing emphasis on personalized medicine, where rare biomarkers often play a pivotal role, has made collection and stabilization practices a focal point for improving diagnostic accuracy and enabling advanced biomarker research.

What Methods Are Used for Specimen Collection and Stabilization of Rare Biomarkers?

Collecting and stabilizing specimens containing rare biomarkers requires specialized techniques to preserve their structure and functionality. Blood-based biomarkers are frequently collected in specialized tubes containing anticoagulants and stabilizing agents, such as EDTA or heparin, which prevent coagulation and preserve cell-free DNA, RNA, and proteins. For example, for rare biomarkers like circulating tumor DNA (ctDNA), blood collection tubes with proprietary stabilization agents help prevent cellular degradation and maintain nucleic acid integrity for several days, allowing for more accurate downstream analysis. Plasma and serum separation are also essential steps in the stabilization process, as these fluids contain critical biomarker information once separated from whole blood.

For urine and saliva samples, immediate cooling or addition of preservatives is often required to prevent the breakdown of sensitive biomarkers. Snap freezing—immediately freezing specimens in liquid nitrogen—is commonly used for tissue samples and other biological specimens to preserve proteins and nucleic acids. Stabilization buffers are also used for RNA and protein-based biomarkers to prevent rapid degradation. Moreover, advancements in microfluidics and biopreservation technologies enable the preservation of rare biomarkers at room temperature, making specimen handling and transport easier. Ensuring that each sample is carefully processed and stored according to specific requirements for each biomarker type helps maintain sample integrity, allowing researchers to obtain reliable and reproducible data in biomarker studies.

How Are Technological Advancements Improving Rare Biomarker Collection and Stabilization?

Technological innovations are advancing the collection and stabilization of rare biomarkers, enabling higher sensitivity, accuracy, and preservation. Microfluidic devices allow for the collection and analysis of very small sample volumes, preserving rare biomarkers and minimizing degradation risks. These devices can separate and concentrate biomarkers directly from the sample, eliminating the need for extensive processing and improving efficiency in biomarker isolation. Additionally, stabilizing agents have been formulated to maintain biomarker stability for longer periods, even at room temperature. This reduces the dependency on cold chain logistics and simplifies sample handling and storage, particularly for remote and field-based specimen collection.

Digital PCR (dPCR) and next-generation sequencing (NGS) have also transformed rare biomarker analysis by providing ultra-sensitive detection capabilities, allowing researchers to detect and quantify biomarkers that are present in extremely low concentrations. Furthermore, biosensor-based collection devices are being developed to detect rare biomarkers immediately upon collection, bypassing the need for extensive stabilization and transport processes. Automation and robotic systems are also enhancing specimen collection and handling, reducing the risk of human error and contamination while ensuring that stabilization protocols are followed with precision. These technologies are pivotal in enabling robust biomarker collection and preservation, facilitating the development of more accurate diagnostic tools and personalized treatments.

What Is Driving the Growth in the Rare Biomarker Specimen Collection and Stabilization Market?

The growth in the rare biomarker specimen collection and stabilization market is driven by the increasing demand for precision medicine, advancements in diagnostic technologies, and the rise in complex diseases requiring early detection. As the healthcare industry shifts toward individualized treatment, the need for reliable biomarkers to guide targeted therapies has surged, especially for diseases like cancer and neurological disorders. Researchers and clinicians rely on accurate and stable biomarker data to make informed decisions, and investments in high-quality specimen collection and stabilization tools are essential to meet this demand.

In addition, regulatory requirements and standards for biomarker-based diagnostics are becoming more stringent, especially as companion diagnostics and biomarker-driven therapies gain traction. The need for standardized collection and stabilization protocols is prompting healthcare providers, research institutions, and diagnostic companies to adopt advanced solutions that ensure data accuracy and reproducibility. Growing investment in research and development to identify new biomarkers has also fueled demand for technologies that support rare biomarker preservation. With these factors collectively driving growth, the market for rare biomarker specimen collection and stabilization is poised to expand, paving the way for breakthroughs in diagnostic precision and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Rare Biomarkers Specimen Collection and Stabilization market in terms of US$ Million by the following End-Use; Product Type, and Geographic Regions/Countries:

Segments:
Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA); End-Use (Research, Diagnostics)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• Advanced Cell Diagnostics, Inc.
• Agena Bioscience
• ANGLE plc
• ApoCell, Inc.
• AS One InternationalNTERNATIONAL
• BioChain Institute, Inc.
• Biolidics Limited
• Biomatrica
• Bio-Techne Corporation
• BioVision, Inc.
• Caltag Medsystems Limited
• Cytomark Ltd.
• DNA Genotek, Inc.
• Epic Sciences
• EpiGentek Group Inc.
• F. Hoffmann-La Roche Ltd
• Fluxion Biosciences, Inc.
• Geno Technology Inc.
• Genomax Technologies Pte Ltd.
• GILUPI GmbH
• LifeSpan BioSciences, Inc.
• MagBio Genomics Inc.
• Menarini Silicon Biosystems
• MyBioSource.com
• Norgen Biotek Corp.
• Novus Biologicals, LLC
• OraSure Technologies Inc.
• Precision for Medicine, Inc.
• Promega Corporation
• QIAGEN
• Rarecells Diagnostics SAS
• RareCyte, Inc.
• siemens Healthineers
• SiO2 Materials Science
• STEMCELL Technologies Inc.
• Streck, Inc.
• Thermo Fisher Scientific, Inc.
• Vortex Biosciences
• VyCAP B.V.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.